TEVA PHARMACEUTICAL INDUSTRIES LTD Royalty Expense
Financial Statements › Expense Statement › Operating Expenses
us-gaap:RoyaltyExpense · last filed 2026-02-03
- TEVA PHARMACEUTICAL INDUSTRIES LTD royalty expense for fiscal 2025 was $740.00M, a 2.92% increase from fiscal 2024.
- TEVA PHARMACEUTICAL INDUSTRIES LTD royalty expense for fiscal 2024 was $719.00M, a 32.41% increase from fiscal 2023.
- TEVA PHARMACEUTICAL INDUSTRIES LTD royalty expense for fiscal 2023 was $543.00M, a 3.04% decline from fiscal 2022.
- TEVA PHARMACEUTICAL INDUSTRIES LTD royalty expense for fiscal 2022 was $560.00M, a 7.28% increase from fiscal 2021.
| Period end | Royalty Expense 12 month |
|---|---|
| 2025-12-31 | $740.00M 10-K · filed 2026-02-03 |
| 2024-12-31 | $719.00M 10-K · filed 2026-02-03 |
| 2023-12-31 | $543.00M 10-K · filed 2026-02-03 |
| 2022-12-31 | $560.00M 10-K · filed 2025-02-05 |
| 2021-12-31 | $522.00M 10-K · filed 2024-02-12 |
| 2020-12-31 | $505.00M 10-K · filed 2023-02-10 |
| 2019-12-31 | $403.00M 10-K · filed 2022-02-09 |
| 2018-12-31 | $536.00M 10-K · filed 2021-02-10 |
| 2017-12-31 | $956.00M 10-K · filed 2020-02-21 |
| 2016-12-31 | $814.00M 10-K · filed 2019-02-19 |
| 2015-12-31 | $911.00M 10-K · filed 2018-02-12 |
| 2014-12-31 | $987.00M 20-F · filed 2017-02-15 |
| 2013-12-31 | $1.10B 20-F · filed 2016-02-11 |